These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 32862311)

  • 21. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
    Drakopoulou M; Soulaidopoulos S; Oikonomou G; Tousoulis D; Toutouzas K
    Curr Vasc Pharmacol; 2020; 18(5):488-506. PubMed ID: 32056527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors.
    Kita J; Tamai M; Arima K; Nakashima Y; Suzuki T; Kawashiri SY; Okada A; Koga T; Yamasaki S; Nakamura H; Origuchi T; Aramaki T; Nakashima M; Fujikawa K; Tsukada T; Ida H; Aoyagi K; Uetani M; Eguchi K; Kawakami A
    Mod Rheumatol; 2012 Apr; 22(2):195-201. PubMed ID: 21898075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
    Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg JE; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
    Ann Rheum Dis; 2020 Jun; 79(6):685-699. PubMed ID: 31969328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents.
    Infante M; Padilla N; Alejandro R; Caprio M; Della-Morte D; Fabbri A; Ricordi C
    Medicina (Kaunas); 2022 Apr; 58(5):. PubMed ID: 35629988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns in use and costs of conventional and biologic disease-modifying anti-rheumatic drugs in Australia.
    Donges E; Staatz CE; Benham H; Kubler P; Hollingworth SA
    Clin Exp Rheumatol; 2017; 35(6):907-912. PubMed ID: 28421991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased Staphylococcus aureus Nasal Carriage Rates in Rheumatoid Arthritis Patients on Biologic Therapy.
    Goodman SM; Nocon AA; Selemon NA; Shopsin B; Fulmer Y; Decker ME; Grond SE; Donlin LT; Figgie MP; Sculco TP; Russell LA; Henry ME; Bass AR; Miller AO; Sculco PK
    J Arthroplasty; 2019 May; 34(5):954-958. PubMed ID: 30733073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis.
    Kang EH; Liao KP; Kim SC
    Curr Rheumatol Rep; 2018 May; 20(7):42. PubMed ID: 29846814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Homeostasis and Disorder of Musculoskeletal System.Progress in the treatment of rheumatoid arthritis.].
    Tanaka Y
    Clin Calcium; 2018; 28(3):395-401. PubMed ID: 29512532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.
    Fleischmann R; Iqbal I; Nandeshwar P; Quiceno A
    Drug Saf; 2002; 25(3):173-97. PubMed ID: 11945114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The influence of disease-modifying anti-rheumatic drugs and corticosteroids on the association between rheumatoid arthritis and skin cancer: a nationwide retrospective case-control study in Taiwan.
    Tseng HW; Lu LY; Lam HC; Tsai KW; Huang WC; Shiue YL
    Clin Exp Rheumatol; 2018; 36(3):471-478. PubMed ID: 29303707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological characterisation of CR6086, a potent prostaglandin E
    Caselli G; Bonazzi A; Lanza M; Ferrari F; Maggioni D; Ferioli C; Giambelli R; Comi E; Zerbi S; Perrella M; Letari O; Di Luccio E; Colovic M; Persiani S; Zanelli T; Mennuni L; Piepoli T; Rovati LC
    Arthritis Res Ther; 2018 Mar; 20(1):39. PubMed ID: 29490676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of biologics in the treatment of childhood rheumatic diseases.
    Arkachaisri T; Lehman TJ
    Curr Rheumatol Rep; 2000 Aug; 2(4):330-6. PubMed ID: 11123079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs.
    Pavelka K; Kavanaugh AF; Rubbert-Roth A; Ferraccioli G
    Rheumatology (Oxford); 2012 Jul; 51 Suppl 5():v12-21. PubMed ID: 22718922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of tuberculosis among patients with rheumatoid arthritis using TNF blockers in Brazil: data from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (Registro Brasileiro de Monitoração de Terapias Biológicas - BiobadaBrasil).
    Yonekura CL; Oliveira RDR; Titton DC; Ranza R; Ranzolin A; Hayata AL; Duarte Â; Silveira IG; Carvalho HMDS; Moraes JCB; Abreu MM; Valim V; Bianchi W; Brenol CV; Pereira IA; Costa I; Macieira JC; Miranda JRS; Guedes-Barbosa LS; Bertolo MB; Sauma MFLDC; Silva MBG; Freire M; Scheinberg MA; Toledo RA; Oliveira SKF; Fernandes V; Pinheiro MM; Castro G; Vieira WP; Baaklini CE; Ruffino-Netto A; Pinheiro GDRC; Laurindo IMM; Louzada-Junior P
    Rev Bras Reumatol Engl Ed; 2017; 57 Suppl 2():477-483. PubMed ID: 28739353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of resuming biologic DMARDs in patients who develop tuberculosis after anti-TNF treatment.
    Cho SK; Kim D; Won S; Han M; Lee J; Jang EJ; Kim TH; Bae SC; Sung YK
    Semin Arthritis Rheum; 2017 Aug; 47(1):102-107. PubMed ID: 28216194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Biologic therapy of rheumatoid arthritis].
    Damjanov N; Vojinović J
    Srp Arh Celok Lek; 2009; 137(3-4):205-10. PubMed ID: 19459571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.